Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,117Revenue $M450Net Margin (%)8.2Z-Score3.2
Enterprise Value $M1,088EPS $0.9Operating Margin %12.9F-Score5
P/E(ttm))58.5Cash Flow Per Share $0.9Pre-tax Margin (%)11.8Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %4.4Quick Ratio3.9Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %1.7Current Ratio4.7Lower Leverage y-yN
Price/Cash Flow17.0y-y EBITDA Growth Rate %-4.2ROA % (ttm)4.5Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)7.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M37.9ROI % (ttm)5.1Gross Margin Increase y-yN

Gurus Latest Trades with EBS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EBSJoel Greenblatt 2014-09-30 Sold Out -0.06%$21.31 - $24.9
($22.93)
$ 29.4622%Sold Out0
EBSJohn Burbank 2014-06-30 Sold Out -0.01%$20.42 - $26.78
($23.3)
$ 29.4621%Sold Out0
EBSJoel Greenblatt 2014-03-31 Buy 0.1%$22.85 - $28.09
($25.19)
$ 29.4614%New holding258,760
EBSJohn Rogers 2014-03-31 Sold Out -0.04%$22.85 - $28.09
($25.19)
$ 29.4614%Sold Out0
EBSJohn Burbank 2014-03-31 Buy 0.01%$22.85 - $28.09
($25.19)
$ 29.4614%New holding7,987
EBSJohn Rogers 2013-12-31 Add0.02%$17.71 - $23.95
($20.84)
$ 29.4629%Add 105.79%122,650
EBSJohn Rogers 2013-09-30 Add0.01%$15.22 - $19.43
($17.88)
$ 29.4639%Add 116.73%59,600
EBSJohn Rogers 2013-06-30 Buy 0.01%$13.08 - $15.73
($14.48)
$ 29.4651%New holding27,500
EBSJoel Greenblatt 2013-03-31 Sold Out -0.14%$13.95 - $16.9
($15.67)
$ 29.4647%Sold Out0
EBSJoel Greenblatt 2012-12-31 Buy 0.14%$12.91 - $16.09
($14.64)
$ 29.4650%New holding147,099
EBSKen Fisher 2012-12-31 Add$12.91 - $16.09
($14.64)
$ 29.4650%Add 21.09%401,700
EBSJoel Greenblatt 2011-12-31 Sold Out -0.08%$15.43 - $19.64
($17.41)
$ 29.4641%Sold Out0
EBSJoel Greenblatt 2011-06-30 Reduce-0.05%$20.66 - $24.98
($23.2)
$ 29.4621%Reduce -20.74%26,620
EBSKen Fisher 2011-06-30 Add0.01%$20.66 - $24.98
($23.2)
$ 29.4621%Add 160.57%300,305
EBSJoel Greenblatt 2011-03-31 Add0.17%$20.64 - $24.55
($22.62)
$ 29.4623%Add 243.58%33,585
EBSKen Fisher 2011-03-31 Buy 0.01%$20.64 - $24.55
($22.62)
$ 29.4623%New holding115,250
EBSJoel Greenblatt 2010-12-31 Buy 0.07%$17.59 - $23.8
($19.23)
$ 29.4635%New holding9,775
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EBS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


EBS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
El-Hibri FuadChairman, 10% Owner 2015-01-20Sell15,325$27.673.07view
Richard RonaldDirector 2014-12-26Sell5,000$281.86view
Richard RonaldDirector 2014-12-17Sell5,000$275.63view
El-Hibri FuadChairman, 10% Owner 2014-12-11Sell119,341$269.69view
El-Hibri FuadChairman, 10% Owner 2014-11-28Sell34,577$2514.08view
El-Hibri FuadChairman, 10% Owner 2014-11-25Sell9,014$2514.08view
Harsanyi ZsoltDirector 2014-11-25Sell8,000$24.8214.91view
El-Hibri FuadChairman, 10% Owner 2014-11-12Sell2,311$2514.08view
Kramer RobertEVP & CFO 2014-11-07Sell2,625$2418.83view
El-Hibri FuadChairman, 10% Owner 2014-09-02Sell1,633$2514.08view

Press Releases about EBS :

    Quarterly/Annual Reports about EBS:

    News about EBS:

    Articles On GuruFocus.com
    Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
    Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
    Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
    Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
    Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 
    Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 25,000 Shares Apr 29 2010 

    More From Other Websites
    FDA approves Emergent BioSolutions' inhaled anthrax treatment Mar 25 2015
    FDA approves Emergent BioSolutions' anthrax treatment Mar 25 2015
    Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in... Mar 25 2015
    Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in... Mar 25 2015
    Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next... Mar 24 2015
    Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next... Mar 24 2015
    U.S. funding research of better anthrax vaccine -health officials Mar 23 2015
    Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog Mar 17 2015
    Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the... Mar 16 2015
    Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the... Mar 16 2015
    EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2015
    EMERGENT BIOSOLUTIONS INC. Financials Mar 13 2015
    Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides... Mar 12 2015
    Emergent BioSolutions, MorphoSys Start Cancer Drug Study - Analyst Blog Mar 10 2015
    Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015
    Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015
    MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015
    MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology... Mar 09 2015
    Emergent BioSolutions Lags Earnings, Cancels 2015 View - Analyst Blog Mar 06 2015
    06.03.2015 - Erste Bank und Sparkassen Increase Operating Earnings to EUR 947 m. (+16%) Mar 06 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK